Intellia Therapeutics Finalizes Terms for $400M At-The-Market Offering

summarizeSummary

Intellia Therapeutics filed a prospectus supplement detailing the terms of its expanded $400 million At-The-Market (ATM) offering, enabling the company to sell common stock to fund operations and clinical development.

check_boxKey Events

• Formalizes $400M ATM Offering

  Intellia Therapeutics filed a 424B5 prospectus supplement to finalize the terms of its expanded At-The-Market (ATM) equity offering, allowing the sale of up to $400 million in common stock.

• Significant Potential Dilution

  The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders.

• Capital for Clinical Development

  Proceeds from the offering are intended to fund research and clinical development of pipeline candidates, including the recently cleared MAGNITUDE Phase 3 trial, working capital, and general corporate purposes, extending the company's liquidity.

• Follows Concurrent 8-K Announcement

  This filing provides the detailed prospectus for the ATM program expansion, which was announced in a separate 8-K filing on the same date, March 2, 2026.

auto_awesomeAnalysis

This 424B5 prospectus supplement formalizes the terms of Intellia Therapeutics' expanded At-The-Market (ATM) equity offering, allowing the company to sell up to $400 million in common stock. This filing provides the detailed legal framework for the ATM program, which was announced in a separate 8-K filing on the same day, March 2, 2026. The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders. While dilutive, this substantial capital raise is crucial for funding ongoing research and clinical development, including the recently cleared MAGNITUDE Phase 3 trial, and extends the company's liquidity runway. Investors should monitor the pace of ATM sales and their impact on share price.